<DOC>
	<DOCNO>NCT01157234</DOCNO>
	<brief_summary>This study investigate blood pressure lower efficacy nebivolol among renal transplant recipient calcineurin inhibitor believe contribute hypertension sympathetic nervous system ( SNS ) activation decrease prostaglandin nitric oxide production . Hypotheses : 1 . There significant difference effect 12 month Nebivolol versus Metoprolol treatment plasma nitric oxide level hypertensive renal transplant patient . 2 . There significant difference effect 12 month Nebivolol versus Metoprolol treatment estimate glomerular filtration rate hypertensive renal transplant patient . 3 . There significant difference effect 12 month Nebivolol versus Metoprolol treatment systolic , diastolic mean arterial blood pressure hypertensive renal transplant patient .</brief_summary>
	<brief_title>Nebivolol Effect Nitric Oxide Levels , Blood Pressure , Renal Function Kidney Transplant Patients</brief_title>
	<detailed_description>Nitric Oxide ( NO ) play plethora function kidney include vascular hemodynamic regulation , fluid electrolyte transport , important component pressure natriuresis tubule-glomerular feedback . Deficient NO level associate oxidative stress condition like hypertension , diabetes mellitus , cardiovascular disease . NO deficiency identify state chronic progressive renal disease alter NO production and/or decrease bioavailability believe characterize endothelial dysfunction resistant hypertension renal failure . It show kidney transplantation improve endothelium-dependent vasodilation patient end-stage renal disease ( ESRD ) NO activity significantly increase transplantation . However , calcineurin inhibitor drug use anti-rejection regimen reduce endothelial NO production aggravate hypertension vascular renal mechanism . In turn , uncontrolled elevation blood pressure associate increase renal allograft failure post-transplant mortality . In absence randomize clinical trial antihypertensive drug optimal blood pressure goal kidney transplant recipient . There scientifically-robust consensus specific drug use among transplant patient . Nebivolol , third generation B1-selective B-blocker show similar BP-lowering effect B-blockers , angiotensin convert enzyme ( ACE ) inhibitor angiotensin II receptor blocker ( ARB ) drug , calcium channel blocker . Nebivolol ameliorate hypertension increase NO release , promote arterial venous vasodilatation beta-blockade . Nebivolol beneficial effect kidney allograft . Studies animal transplant show nebivolol could reduce ischemia-induced reperfusion injury , alleviate renal perfusion pressure increase NO release associate vasodilation renal vasculature . These effect see old generation B-blockers like propranolol bisoprolol . Finally , surgically reduce renal mass , nebivolol demonstrated attenuate collagen type 1 expression lessen glomerular interstitial fibrosis . In study , effect nebivolol metoprolol change NO level baseline 12th month treatment compare . Similarly , effect two drug change renal function , blood pressure , blood pressure regimen baseline month-12 treatment also compare .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Men woman least 18 year age recipients solitary kidney combine kidneypancreas transplant within last twenty four month Current diagnosis hypertension Normal hepatic enzyme Estimated creatinine clearance ( cockcroftgault formula ) &gt; or= 30 ml/min Any contraindication take betablockers , specifically Nebivolol Metoprolol . Conditions : ( bradycardia heart rate ( HR ) &lt; 60 beat per minute , heart block &gt; 1st degree , decompensated cardiac failure , sick sinus syndrome ( unless permanent pacemaker place ) , severe hepatic impairment ( define elevation aspartamine aminotransferase , alanine aminotransferase , bilirubin level three time upper limit normal reference range ) , severe peripheral arterial circulatory disorder , history bronchospasm /or asthma /or regular medication inhale bronchodilator . , medical condition opinion investigator may interfere subject 's ability successfully complete protocol . Any medical condition , opinion Principal Investigator , might compromise safety subject participate protocol hypotension require antihypertensive medication . Any serious systemic disease might complicate management reduce life expectancy . Uncontrolled hypertension define systolic blood pressure ( SBP ) &gt; 210 diastolic blood pressure ( DBP ) &gt; 120 mm Hg . Symptomatic hypotension Previous intolerance beta blocker Cerebrovascular accident within 3 month randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Kidney transplantation</keyword>
	<keyword>Renal function</keyword>
	<keyword>Nitric Oxide</keyword>
	<keyword>Nebivolol</keyword>
</DOC>